Sino Biopharmaceutical (1177.HK): Strong downward momentum
Sino Biopharmaceutical (1177), a pharmaceutical company, reported that 9-month underlying net income fell 17.9% on year to 2.29 billion yuan on revenue of 18.13 billion yuan, down 6.2%. After the release of the 3Q result, the stock slumped 10%.
Besides, Citibank cut the company target prices from HK$12.8 to HK$11.60.
From a technical point of view, the stock broke below a rising trend line from June 2019. The RSI broke below its oversold level at 30, suggesting a strong downward momentum. The declining 20-day moving average is also acting as key resistance now. Bearish readers could set the resistance level at HK$7.60, while resistance levels would be located at HK$6.15 and HK$6.25.
![](/en-au/-/media/research/global/2020/12/120720sinoci.png)
Source: GAIN Capital, TradingView
Besides, Citibank cut the company target prices from HK$12.8 to HK$11.60.
From a technical point of view, the stock broke below a rising trend line from June 2019. The RSI broke below its oversold level at 30, suggesting a strong downward momentum. The declining 20-day moving average is also acting as key resistance now. Bearish readers could set the resistance level at HK$7.60, while resistance levels would be located at HK$6.15 and HK$6.25.
![](/en-au/-/media/research/global/2020/12/120720sinoci.png)
Source: GAIN Capital, TradingView
Latest market news
Yesterday 01:32 PM
Yesterday 09:35 AM
Yesterday 07:23 AM
Yesterday 04:48 AM
Yesterday 12:17 AM
July 25, 2024 10:39 PM